• UPF3A Is Ubiquitously Expressed NMD Factor in Mouse Tissues

  2026-05-09

  This study overturns previous assumptions by demonstrating that UPF3A protein is present in nearly all major mouse tissues, not just the testis. Quantitative analyses reveal that UPF3A levels frequently match or surpass those of UPF3B, suggesting a broader role for UPF3A in nonsense-mediated mRNA decay (NMD) and tissue homeostasis.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Technical Workflow Gu

  2026-05-08

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) addresses the need for reproducible detection of HMGB1 protein across Western blot, immunohistochemistry, and flow cytometry applications in human, mouse, and rat samples. It is not validated for diagnostic or therapeutic use and is intended strictly for research workflows requiring precise chromatin protein detection.

• T0070907: Precision PPARγ Antagonist for Cell Signaling Stud

  2026-05-08

  T0070907 is a highly potent PPARγ antagonist enabling targeted disruption of PPARγ signaling in adipogenesis and cancer biology. Its nanomolar affinity and selectivity facilitate reliable, reproducible modulation of transcriptional networks across diverse cellular models, making it a preferred tool for mechanistic research and advanced screening platforms.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Technical Workflow

  2026-05-07

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for sensitive, specific detection of rabbit primary antibodies in research immunoassays such as Western blot, ELISA, and immunohistochemistry. It should not be used in diagnostic or clinical settings. Researchers benefit from its affinity purification and HRP conjugation, which together facilitate robust signal amplification with minimal background.

• α2-AR Agonists in Immune Modulation for Osteosarcoma Researc

  2026-05-07

  This thought-leadership article explores how selective α2-adrenergic receptor agonists, particularly 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, are transforming translational research in immune rejection modulation and post-surgery osteosarcoma recurrence treatment. By blending mechanistic insight with strategic experimental guidance, it empowers researchers to optimize receptor signaling studies and highlights APExBIO’s high-purity compound as a best-in-class solution for advancing immune-oncology research.

• Pentoxifylline Attenuates Hyperinflammation in Preterm Monoc

  2026-05-06

  Schüller et al. provide the first in-depth in vitro analysis of pentoxifylline’s (PTX) immunomodulatory effects on LPS-stimulated monocytes from preterm infants, revealing age-dependent suppression of surface activation markers, pro-inflammatory cytokines, and TLR4 signaling. These findings clarify PTX's potential as an adjunctive immunomodulatory therapy in neonatal sepsis and inform translational strategies targeting innate immune dysregulation.

• MOG (35-55): Optimizing EAE Models for Multiple Sclerosis Re

  2026-05-06

  MOG (35-55) Peptide empowers researchers to induce robust, reproducible autoimmune encephalomyelitis—enabling high-fidelity modeling of multiple sclerosis and neuroinflammation. Learn how to refine protocols, troubleshoot key steps, and leverage new mechanistic insights for translational breakthroughs.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Technical Use Guide

  2026-05-05

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) enables robust detection of HMGB1 across Western blot, immunohistochemistry, and flow cytometry in human, mouse, and rat research samples. It is not validated for diagnostic or therapeutic applications and is strictly intended for scientific research workflows requiring reliable chromatin protein detection.

• PARP7 Inhibition Stabilizes STAT1/2 and Mitigates EAE in Mic

  2026-05-05

  Xu et al. reveal that PARP7 suppresses type I interferon signaling via ADP-ribosylation and autophagic degradation of STAT1/STAT2, and that its inhibition alleviates MOG (35-55)-induced experimental autoimmune encephalomyelitis in mice. These findings offer mechanistic insight and suggest PARP7 as a potential target for multiple sclerosis therapy.

• Deoxynivalenol-Induced Liver Injury: Mitophagy and Nrf2 Path

  2026-05-04

  This article examines the mechanistic findings of a recent study elucidating how deoxynivalenol (DON) induces liver injury via overactivation of PINK1/Parkin-mediated mitophagy and suppression of the p62-Keap1-Nrf2 cytoprotective pathway. The work clarifies key molecular events underlying DON hepatotoxicity, offering a foundation for experimental modeling and therapeutic intervention.

• Methotrexate as a Folate Antagonist: Applied Workflows & Opt

  2026-05-04

  Methotrexate empowers researchers to dissect apoptosis, immunosuppression, and anti-inflammatory mechanisms with unmatched rigor. This article provides actionable workflow enhancements, critical troubleshooting strategies, and protocol parameters to maximize reproducibility using APExBIO’s validated Methotrexate in bench research.

• LL-37 and Truncated Peptides: Distinct Antibiofilm Actions I

  2026-05-03

  This study dissects the differential biocidal and antibiofilm activities of the human peptide LL-37 and its truncated mimetics, KE-18 and KR-12, against major biofilm-forming pathogens. The findings reveal that truncated peptides can retain or even enhance specific antimicrobial properties, informing the rational design of targeted anti-infective agents for device-related and biofilm-associated infections.

• Palonosetron Hydrochloride in Chemotherapy-Induced Nausea Co

  2026-05-02

  The reference study by Ruhlmann & Herrstedt critically evaluates palonosetron hydrochloride as a next-generation 5-HT3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (CINV). Its unique pharmacological properties, including allosteric receptor binding and an extended half-life, are examined for their clinical value relative to earlier antiemetic agents.

• EDI3 Inhibition Reduces Growth in HER2-Resistant Breast Canc

  2026-05-01

  Keller et al. identify glycerophosphodiesterase EDI3 as a metabolic vulnerability in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy. Targeting EDI3 impairs cell viability and tumor growth, pointing to new therapeutic opportunities in overcoming resistance.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody: Signal Amplification

  2026-05-01

  Explore the advanced mechanism and scientific rationale behind the Cy5 Goat Anti-Mouse IgG (H+L) Antibody for high-sensitivity immunoassays. This article uniquely dissects signal amplification strategies and cross-domain innovations with practical assay guidance.

16020 records 1/1068 page Next 12345 下5页 Last page